Long-Term Safety of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
David T. Rubin 1, Bruce A. C. Cree 2, Douglas C. Wolf 3, Olga Alekseeva 4, Lorna Charles 5, AnnKatrin Petersen 5, James K. Sheffield 5, Chun-Yen Cheng 5, Jon V. Riolo 5, Diego Silva 5, Fred D. Lublin 6, Jeffrey A. Cohen 7, Silvio Danese 8
1 University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA; 2 Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; 3 Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, USA; 4 Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia; 5 Bristol Myers Squibb, Princeton, NJ, USA; 6 Mount Sinai Medical Center, New York, NY, USA; 7 Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA; 8 Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy
;
